Bluejay Diagnostics (BJDX) Common Equity (2020 - 2026)

Bluejay Diagnostics has disclosed Common Equity across 7 years of filings, most recently posting $4.2 million for Q1 2026.

• Common Equity for Q1 2026 came in at $4.2 million, up 8.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 million (up 8.14% YoY), and the FY2025 annual result was $6.0 million, up 4.29% from the prior year.
• Common Equity came in at $4.2 million for Q1 2026 at Bluejay Diagnostics, down from $6.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $18.5 million in Q1 2022 to a low of $2.9 million in Q4 2023.
• The 5-year median for Common Equity is $6.0 million (2025), against an average of $7.8 million.
• Across the five-year window, Common Equity surged 13389.68% in 2022 and slumped 74.92% in 2023, its largest moves.
• Bluejay Diagnostics' Common Equity stood at $11.5 million in 2022, then plunged by 74.92% to $2.9 million in 2023, then surged by 97.92% to $5.7 million in 2024, then gained by 4.29% to $6.0 million in 2025, then slumped by 30.03% to $4.2 million in 2026.
• The last three Common Equity figures came in at $4.2 million (Q1 2026), $6.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.